Adjunctive aripiprazole in the treatment of risperidone/paliperidone-induced hyperprolactinemia. Influence of catechol-O-methyltransferase and MAOA polymorphisms

被引：0
|
作者：
Arnaiz, A. [1 ]
Zumarraga, M. [1 ]
Olivas, O. [2 ]
Arrue, A. [1 ]
Gaton, M. [3 ]
Erkoreka, L. [4 ]
Zamalloa, M. [1 ]
Basterreche, N. [1 ]
机构：
[1] Hosp Zamudio, Red Salud Mental Bizkaia, Zamudio, Bizkaia, Spain
[2] CSM Gernika, Red Salud Mental Bizkaia, Gernika, Bizkzia, Spain
[3] Ctr Dia Erandio, Red Salud Mental Bizkaia, Erandio, Bizkaia, Spain
[4] CSM Barakaldo, Red Salud Mental Bizkaia, Baracaldo, Bizkaia, Spain
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2017年 / 27卷
关键词：
MONOAMINE-OXIDASE; GENOTYPES;
D O I：
10.1016/S0924-977X(17)31223-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.1.g.026
引用
收藏
页码：S653 / S654
页数：2
相关论文
共 40 条
  • [1] Factors affecting the efficacy of adjunctive aripiprazole in risperidone- or paliperidone-induced hyperprolactinemia
    Arnaiz Munoz, A.
    Olivas, O.
    Erkoreka, L.
    Gaton, M. A.
    Barreiro, A.
    Rodriguez, J.
    Arrue, A.
    Basterreche, N.
    Zumarraga, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S125 - S126
  • [2] Influence of genetic polymorphisms on hyperprolactinemia caused by risperidone or paliperidone and on the effect of adjunctive aripiprazole
    Montero-Gonzalez, G.
    Arnaiz, A.
    Arrue, A.
    Olivas, O.
    Gordo, E.
    Marin, E.
    Erkoreka, L.
    Zumarraga, M.
    Basterreche, N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S249 - S250
  • [3] Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia
    Ranjbar, Fatemeh
    Sadeghi-Bazargani, Homayoun
    Khams, Parisa Niari
    Arfaie, Asghar
    Salari, Azim
    Farahbakhsh, Mostafa
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 549 - 555
  • [4] Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance
    Gao, Shugui
    Hu, Zhenyu
    Cheng, Jia
    Zhou, Wenhua
    Xu, Yongming
    Xie, Shuguang
    Liu, Shiyan
    Li, Zaizhong
    Guo, Junming
    Dong, Jianyi
    Huang, Minfang
    CLINICAL BIOCHEMISTRY, 2012, 45 (10-11) : 787 - 792
  • [5] Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia
    Han, Jiyang
    Li, Yan
    Wang, Xumei
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 : 2935 - 2943
  • [6] Entacapone:: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease
    Najib, J
    CLINICAL THERAPEUTICS, 2001, 23 (06) : 802 - 832
  • [7] Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy
    Anttila, Sami
    Huuhka, Kaija
    Huuhka, Martti
    Illi, Ari
    Rontu, Riikka
    Leinonen, Esa
    Lehtimaki, Terho
    PHARMACOGENOMICS JOURNAL, 2008, 8 (02): : 113 - 116
  • [8] Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy
    Sami Anttila
    Kaija Huuhka
    Martti Huuhka
    Ari Illi
    Riikka Rontu
    Esa Leinonen
    Terho Lehtimäki
    The Pharmacogenomics Journal, 2008, 8 : 113 - 116
  • [9] Dose-Dependent Effects of Adjunctive Treatment With Aripiprazole on Hyperprolactinemia Induced by Risperidone in Female Patients With Schizophrenia
    Yasui-Furukori, Norio
    Furukori, Hanako
    Sugawara, Norio
    Fujii, Akira
    Kaneko, Sunao
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (05) : 596 - 599
  • [10] Polymorphisms in the catechol-O-methyltransferase (COMT) gene influence plasma total homocysteine levels
    Tunbridge, Elizabeth M.
    Harrison, Paul J.
    Warden, Donald R.
    Johnston, Carole
    Refsum, Helga
    Smith, A. David
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2008, 147B (06) : 996 - 999
1234